[Lymphangioleiomyomatosis: new therapeutic approaches].

[1]  J. Ancochea,et al.  Tratamiento de la linfangioleiomiomatosis con sirolimus , 2011 .

[2]  J. Ancochea,et al.  Lymphangioleiomyomatosis treatment with sirolimus. , 2011, Archivos de bronconeumologia.

[3]  J. Krischer,et al.  Efficacy and safety of sirolimus in lymphangioleiomyomatosis. , 2011, The New England journal of medicine.

[4]  Sociedad Española de Neumología y Cirugía Torácica.  Enfermedad pulmonar obstructiva crónica (EPOC) [50 Congreso Nacional de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR)] , 2011 .

[5]  H. Popper,et al.  European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis , 2010, European Respiratory Journal.

[6]  J. Ancochea,et al.  Lymphangioleiomyomatosis: a study of 72 patients from the Spanish registry. , 2009, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[7]  Vincent J Schmithorst,et al.  Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. , 2008, The New England journal of medicine.

[8]  J. Folkman,et al.  Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. , 2006, The New England journal of medicine.

[9]  A. Geha,et al.  The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[10]  J. Testa,et al.  Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. , 2003, American journal of respiratory and critical care medicine.

[11]  K. Mokbel.  The evolving role of aromatase inhibitors in breast cancer , 2002, International Journal of Clinical Oncology.

[12]  D. Kwiatkowski,et al.  Tuberin Regulates p70 S6 Kinase Activation and Ribosomal Protein S6 Phosphorylation , 2002, The Journal of Biological Chemistry.

[13]  B. Strauss,et al.  Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. , 2002, The American journal of pathology.

[14]  E. Henske,et al.  Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  W. Travis,et al.  Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. , 2000, Archives of pathology & laboratory medicine.

[16]  R. McLelland,et al.  Pulmonary lymphangiomyomatosis responsive to progesterone. , 1980, The New England journal of medicine.